RXcel GmbH develops RNA-based therapeutics for oncology that use engineered RNA molecules to detect cancer cells by the absence of specific genetic markers and to trigger selective therapeutic effectors. The company focuses on conditional-stability RNA designs targeting glioblastoma and reports in vitro/preclinical data alongside academic collaborations on its website.
AI-generated
Offering
Products & services
Industry:Research & Development
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Smart RNA molecules for targeted cancer treatment, focusing on selective activation in tumour cells and minimizing off-target effects.
Glioblastoma research and drug development
Research and development for glioblastoma, including target validation, preclinical proof of concept, in-vitro optimization and preparation for in-vivo studies.
Knowledge
No knowledge articles yet
Once RXcel GmbH has claimed this profile, we'll publish editorial articles and case studies here together.